AstraZeneca Eliminates Advanced Colorectal Cancer Claim For Recentin
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca will no longer file marketing applications in the U.S. and Europe this fall for Recentin (cediranib) in first-line metastatic colorectal cancer after the oral VEGF inhibitor failed to show an overall survival benefit in the Phase III HORIZON II study, the company announced May 28
You may also be interested in...
Phase II non-small cell lung cancer data on cediranib did not meet criteria for Phase III, and showed imbalance in toxicity
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011